BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


SEARCH JOBS

View Clinical Trials from BioPharm Insight


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).


 Key Statistics


Email:
Ownership: Public

Web Site: Ariad Pharmaceuticals, Inc.
Employees:
Symbol: ARIA
 









 Company News
Ariad Pharmaceuticals, Inc. (ARIA) Announces Appointment Of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, As Chief Legal And Administrative Officer 1/22/2015 11:03:18 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Final Decision From European Commission Endorsing Iclusig’s Approved Indications Throughout Europe 1/20/2015 11:13:36 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Key Strategic Objectives For 2015 Expected To Lead Company To Profitability In Three Years 1/13/2015 12:26:49 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Phase 2 Dose-Ranging Trial Of Iclusig (Ponatinib) To Begin By Mid-2015 1/6/2015 9:52:14 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Commercialization Agreement For Iclusig In Seven Central And Eastern European Countries 12/30/2014 8:07:49 AM
MA's Ariad Pharmaceuticals, Inc. (ARIA) Inks $75 Million+ Commercialization Deal In Asia 12/23/2014 6:34:00 AM
Ariad Pharmaceuticals, Inc. (ARIA) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 12/22/2014 9:52:07 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Follow-Up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia 12/9/2014 1:17:29 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial 12/9/2014 1:12:43 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial 12/8/2014 12:01:22 PM
12345678910...